SUMITOMO PHARMA ONCOLOGY
Sumitomo Pharma Oncology is a novel cancer therapeutics developer. Their research includes survival mechanisms and novel protein interactions. They are committed to pursuing a diverse and purposeful pipeline that investigates drivers of treatment resistance and tumor progression.
SUMITOMO PHARMA ONCOLOGY
Industry:
Health Care Oncology Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.oncology.sumitomo-pharma.com
Total Employee:
51+
Status:
Active
Contact:
+1 617 674 6800
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager Font Awesome HSTS Cloudflare JS CDN JS Amazon S3
Similar Organizations
Alacrity Care
Alacrity Care is a technology company developing digital care companions for oncology therapeutics.
BAKX Therapeutics
BAKX Therapeutics is a provider of cancer treatment.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Delve Therapeutics
Delve Therapeutics is investigating novel oncology therapeutics
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Sionna Therapeutics
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Sumitomo Dainippon Pharma Oncology
Sumitomo Dainippon Pharma Oncology is a developer of novel cancer therapeutics.
Current Employees Featured
Official Site Inspections
http://www.oncology.sumitomo-pharma.com
- Host name: ec2-34-202-224-116.compute-1.amazonaws.com
- IP address: 34.202.224.116
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Sumitomo Pharma Oncology"
Sumitomo Pharma America Launches as New Combined …
CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ — Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its …See details»
Innovative Treatments, Science and Technology | Sumitomo …
Dedicated to improving the health and well-being of people around the world. We drive innovative treatments, science, and technology to address patient needs in the critical areas of oncology, …See details»
Sumitomo Pharma Oncology Presents New Data from …
Apr 8, 2022 Sumitomo Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP …See details»
Sumitomo Pharma Oncology, Inc. - MassBio
Dec 15, 2022 Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. …See details»
Sumitomo Dainippon Pharma Oncology - Crunchbase
Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. …See details»
Sumitomo Pharma Oncology - VentureRadar
Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP Oncology is committed …See details»
Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary …
Jun 12, 2023 About Sumitomo Pharma Oncology, Inc. Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organiza on with …See details»
Sumitomo Dainippon Pharma Oncology Presents New Data from …
Inhibitor TP-5809 and CDK9 inhibitor alvocidib. Additionally, Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sumitomo Dainippon Pharma Oncology (SDP Oncology), …See details»
New Expanded Scale, Resources Capabilities - Sumitomo Pharma
Jul 11, 2023 Jatin Shah, Chief Oncology Development Officer of Sumitomo Pharma America, added, "SMPA is uniquely positioned with a strong internal discovery and translational …See details»
Sumitomo Pharma Oncology, Inc. Profile - Medical XPRT
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with …See details»
Sumitomo Pharma Subsidiary Companies in the U.S., Including …
Apr 3, 2023 Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP …See details»
Sumitomo Pharma Subsidiary Companies in the U.S., Including …
Apr 3, 2023 Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP …See details»
Member Spotlight: Q&A with Sumitomo Dainippon …
Feb 1, 2022 Sumitomo Dainippon Pharma Oncology, Inc. (SDP Oncology) is based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. How do your organization’s activities help patients now and into the …See details»
Sumitomo Pharma Oncology - Crunchbase Company Profile
Sumitomo Pharma Oncology is a developer of novel cancer therapeutics.See details»
Sumitomo Pharma Oncology Presents New Data from ... - MassBio
Sumitomo Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP Oncology is …See details»
Sumitomo Pharma Presents Urology and Oncology Data at AUA …
May 7, 2024 About Sumitomo Pharma Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), …See details»
Sumitomo Pharma Oncology Presents Preliminary Data from …
Dec 10, 2022 Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP …See details»
Sumitomo Pharma America to Present Preliminary Clinical Data …
Nov 3, 2023 Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of …See details»
Director, Medical Affairs Strategy (Hematology/Oncology)
Feb 26, 2025 Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma …See details»
Activity and safety of atezolizumab plus carboplatin and paclitaxel …
Thymic epithelial tumours, including thymoma and thymic carcinoma, are rare and develop from the thymus located in the anterior mediastinum, with an incidence rate of 0·15 per 100 000 …See details»